A study to evaluate the effectiveness of epcoritamab in patients with Waldenström's macroglobulinemia that has returned or has not responded to previous treatments.
When Waldenstrom's macroglobulinemia returns after treatment, patients face a journey that requires careful medical decisions, personalized care approaches, and a deep understanding of the options available to manage this rare blood cancer in its recurrent form.
Key points
check_circleWaldenstrom's macroglobulinemia characteristically returns after treatment because no current therapy completely cures this rare blood cancer, but periods of remission can last months, years, or even decades.
check_circleTreatment decisions for recurrence depend critically on how long remission lasted—responses under 12 months typically prompt doctors to choose entirely different therapy types.
check_circleNewer BTK inhibitors like zanubrutinib and acalabrutinib may cause fewer heart-related side effects compared to ibrutinib while maintaining similar effectiveness against the cancer.
check_circleNot all recurrent disease requires immediate treatment—watch-and-wait remains appropriate when blood markers rise but patients feel well without symptoms.
check_circleThe convenience factor matters: oral medications like ibrutinib allow home-based treatment avoiding frequent clinic visits, particularly valuable during situations like pandemic restrictions.
check_circleClinical trials testing chemotherapy-free approaches, novel immunotherapies, and limited-duration treatments represent the future direction for managing this disease.
check_circleGenetic mutations in MYD88 and CXCR4 influence both disease behavior and treatment response, making personalized therapy selection increasingly important.
check_circleCombination approaches mixing different drug classes—like pairing BTK inhibitors with antibodies—are being explored to potentially achieve deeper, longer-lasting responses than single agents.
Navigating the Return of a Rare Blood Cancer
Waldenstrom's macroglobulinemia is a rare type of blood cancer that develops in certain white blood cells called B-lymphocytes. When this disease comes back after an initial round of treatment, it is referred to as recurrent Waldenstrom's macroglobulinemia. Understanding this phase is crucial for patients and their families, as the disease behaves differently than many other cancers. The primary goals of treatment when the disease returns include managing symptoms that affect daily life, slowing the progression of cancer cell growth, and maintaining or improving quality of life for as long as possible.
Treatment decisions for recurrent disease depend heavily on several important factors. These include the stage and severity of the disease at the time of recurrence, how long the remission period lasted after the first treatment, the patient's overall health and fitness level, any other medical conditions they may have, and their personal preferences regarding treatment intensity and side effects. Unlike some cancers that can be completely cured, Waldenstrom's macroglobulinemia cannot currently be eliminated entirely from the body. This means that most patients will experience periods of remission—when symptoms are controlled and cancer markers are reduced—followed by relapse, when the disease becomes active again.
The approach to treating recurrent Waldenstrom's macroglobulinemia has evolved considerably in recent years. Medical societies and expert panels now recognize multiple treatment pathways, including established chemotherapy-based regimens approved by regulatory authorities and newer therapies being tested in clinical trials. Not every patient with recurrent disease needs immediate treatment. If blood tests show rising levels of the abnormal protein but the patient feels well and has no bothersome symptoms, doctors may recommend a watch-and-wait approach, also called active monitoring. Treatment is generally started only when specific criteria are met, such as the presence of significant symptoms, dangerously high levels of the IgM protein, or evidence that the cancer is affecting blood cell production or organ function.
Standard Treatment Approaches for Recurrent Disease
When recurrent Waldenstrom's macroglobulinemia requires treatment, several well-established options are available. The choice of therapy is highly individualized and considers the patient's previous treatment history, how long the remission lasted, current symptoms, and overall physical condition. One of the key considerations is the duration of response to the last treatment. If a patient experienced a remission that lasted less than 12 months after their previous therapy, this is considered a relatively short response, and doctors typically choose a different type of treatment for the relapse.
Rituximab-based regimens are commonly used for recurrent disease. Rituximab is a monoclonal antibody, which is a type of drug that targets specific proteins on the surface of cancer cells. It is often combined with chemotherapy drugs to create more effective treatment combinations. One widely used combination is bendamustine plus rituximab, often abbreviated as BR. This regimen has shown good response rates in patients with relapsed disease. Another option combines rituximab with cyclophosphamide and dexamethasone. These drug combinations work by attacking cancer cells through multiple mechanisms—the rituximab targets the cells directly, while the chemotherapy drugs interfere with the cancer cells' ability to grow and divide.
Bortezomib-containing regimens represent another important class of treatment for recurrent Waldenstrom's macroglobulinemia. Bortezomib is a proteasome inhibitor, which means it blocks a system inside cells that breaks down proteins. When this system is blocked, abnormal proteins build up inside cancer cells, eventually causing them to die. Bortezomib is often combined with rituximab and dexamethasone, a combination known as BDR. Another option adds cyclophosphamide to this mix. These combinations have proven effective for patients whose disease has returned, though they must be used carefully in patients who have nerve damage, as bortezomib can worsen peripheral neuropathy—a condition causing numbness, tingling, or pain in the hands and feet.
Ibrutinib, a drug that belongs to a class called Bruton tyrosine kinase inhibitors (BTK inhibitors), has become an important option for recurrent Waldenstrom's macroglobulinemia. Unlike traditional chemotherapy that kills rapidly dividing cells, ibrutinib works by blocking a specific enzyme that cancer cells need to survive and grow. This drug is particularly valuable for patients who relapsed within 12 months of their previous treatment, including those whose disease did not respond well to rituximab. Ibrutinib is taken as a daily pill, which many patients find more convenient than intravenous infusions. It has been approved specifically for treating Waldenstrom's macroglobulinemia and can be used alone or in combination with rituximab.
The duration of therapy varies depending on the regimen chosen. Chemotherapy-based treatments with rituximab are typically given for a fixed period, often ranging from several months to about 18 months, with treatment given in cycles. Between cycles, patients have rest periods to allow their bodies to recover. In contrast, BTK inhibitors like ibrutinib are usually taken continuously for as long as they remain effective and tolerable.
Each treatment approach carries potential side effects that patients should understand. Chemotherapy-based regimens commonly cause effects related to reduced blood cell counts, including anemia (low red blood cells causing fatigue), neutropenia (low white blood cells increasing infection risk), and thrombocytopenia (low platelets causing bleeding or bruising). Other possible effects include nausea, hair thinning, and increased susceptibility to infections. Bortezomib specifically can cause or worsen neuropathy, leading some doctors to avoid it in patients who already have nerve problems. Patients taking this drug may also experience fatigue, digestive upset, or blood count changes.
Ibrutinib has a different side effect profile. The most significant concerns include an increased risk of irregular heart rhythms, particularly atrial fibrillation, and a slightly elevated risk of bleeding. Some patients experience joint or muscle pain, fatigue, or diarrhea. Because ibrutinib affects blood clotting, patients taking blood-thinning medications need particularly careful monitoring. Regular follow-up appointments and blood tests are essential regardless of which treatment is chosen, allowing doctors to monitor effectiveness and manage any side effects promptly.
Innovative Therapies Being Tested in Clinical Trials
Clinical trials offer access to promising new treatments for patients with recurrent Waldenstrom's macroglobulinemia. These studies are carefully designed to test whether experimental therapies are safe and effective before they become widely available. Participating in a clinical trial may give patients access to cutting-edge treatments that could potentially work better or cause fewer side effects than current standard options. Trials are typically conducted in phases, each with a specific purpose and patient population.
Phase I trials primarily assess the safety of a new drug or treatment approach. Researchers carefully monitor participants to determine the appropriate dose and identify potential side effects. Phase I studies usually involve a small number of patients. Phase II trials expand the investigation to determine whether the treatment is effective against the disease. These studies involve more patients and provide preliminary information about response rates and how long responses last. Phase III trials compare the new treatment directly with current standard therapies to determine whether the experimental approach offers advantages. These are usually large studies involving many medical centers and hundreds of patients.
Several newer BTK inhibitors are being studied specifically for Waldenstrom's macroglobulinemia. Zanubrutinib (also known by the brand name Brukinsa) is a second-generation BTK inhibitor designed to be more selective than ibrutinib, potentially reducing certain side effects like irregular heartbeat. Early studies have shown promising results in patients with relapsed disease, with good response rates and a favorable safety profile. Zanubrutinib works through a similar mechanism as ibrutinib—blocking the enzyme that cancer cells need to survive—but may be better tolerated by some patients, particularly those with heart concerns.
Acalabrutinib (marketed as Calquence) is another next-generation BTK inhibitor being investigated for recurrent Waldenstrom's macroglobulinemia. Like zanubrutinib, acalabrutinib was developed to more specifically target the BTK enzyme while minimizing effects on other pathways that could cause side effects. Clinical trials have evaluated this drug both alone and in combination with rituximab. Preliminary results suggest it can produce meaningful responses in patients whose disease has returned after previous treatment. These newer BTK inhibitors represent important additions to the treatment landscape because they may offer similar benefits to ibrutinib while potentially being easier for some patients to tolerate long-term.
Other classes of drugs are also being explored in clinical trials. Carfilzomib (Kyprolis) is another proteasome inhibitor similar to bortezomib but with a different chemical structure. It is being tested in combination with rituximab and dexamethasone for patients with relapsed disease. Some studies suggest it may be effective even in patients whose disease did not respond to bortezomib, though it must be used cautiously in older patients or those with heart problems.
Ixazomib (Ninlaro) is an oral proteasome inhibitor, meaning it can be taken as a pill rather than requiring intravenous infusion. This is the first proteasome inhibitor available in oral form. It is being studied in combination with rituximab and dexamethasone for recurrent Waldenstrom's macroglobulinemia. The convenience of oral administration makes this an attractive option for patients who prefer to avoid frequent clinic visits for infusions.
Venetoclax, a drug that inhibits a protein called BCL-2, is being investigated for Waldenstrom's macroglobulinemia. BCL-2 is a protein that helps cancer cells avoid natural cell death. By blocking BCL-2, venetoclax can push cancer cells toward dying. This drug has shown effectiveness in other blood cancers and is now being tested specifically for Waldenstrom's macroglobulinemia, particularly in combination with other active agents.
Researchers are also exploring immunotherapy approaches, including drugs that target specific proteins on cancer cells or that help the immune system recognize and attack cancer more effectively. Daratumumab (Darzalex) is a monoclonal antibody that targets a protein called CD38 found on the surface of Waldenstrom's macroglobulinemia cells. It is being tested both alone and in combination with other treatments. Another experimental approach involves CAR T-cell therapy, a highly sophisticated treatment in which a patient's own immune cells are removed from the body, genetically modified to attack cancer cells, and then returned to the patient. A specific CAR T-cell therapy called 19(T2)28z1XX targeting a protein called CD19 is being investigated for Waldenstrom's macroglobulinemia.
Clinical trials for recurrent Waldenstrom's macroglobulinemia are conducted at specialized medical centers around the world. Studies are ongoing in the United States, across Europe including countries like the United Kingdom, Germany, and France, and in other regions. Patient eligibility for specific trials depends on various factors including the type and number of previous treatments received, current health status, blood counts, organ function, and the specific characteristics of the disease. Some trials specifically seek patients whose disease has relapsed after certain types of therapy or within a particular timeframe.
Preliminary results from many of these trials have been encouraging. Several studies of newer BTK inhibitors have reported response rates—meaning the percentage of patients who experience measurable improvement—ranging from approximately 75% to over 90%. Improvements typically include reductions in the abnormal IgM protein levels, decreases in enlarged lymph nodes or organs, improvement in blood counts, and relief of symptoms. The safety profiles of many experimental drugs appear manageable, though careful monitoring remains essential. Some combinations being tested have shown the ability to produce deep responses, meaning very significant reductions in disease markers, which may translate to longer periods of disease control.
Most common treatment methods
Rituximab-based chemoimmunotherapy
Bendamustine plus rituximab (BR) combination showing good response rates in relapsed patients
Rituximab combined with cyclophosphamide and dexamethasone (DRC) for patients needing treatment
Rituximab combined with bortezomib and dexamethasone (BDR) offering multiple-mechanism attack on cancer cells
Bortezomib, dexamethasone, rituximab, and cyclophosphamide (B-DRC) as an intensive option for eligible patients
Fixed-duration treatment typically given in cycles over several months to 18 months
Ibrutinib as single-agent therapy, particularly for patients who relapsed within 12 months of previous treatment
Ibrutinib combined with rituximab for enhanced effectiveness
Zanubrutinib as a second-generation BTK inhibitor with potentially fewer cardiac side effects
Acalabrutinib being tested in clinical trials for improved selectivity
Taken as daily oral medication rather than intravenous infusion
Usually continued long-term as long as treatment remains effective
Proteasome inhibitors
Bortezomib-containing regimens combining with rituximab and steroids
Carfilzomib being studied in combination therapy for relapsed disease
Ixazomib as the first oral proteasome inhibitor being tested with rituximab
Should be avoided or used cautiously in patients with existing neuropathy
Immunotherapy approaches
Daratumumab targeting CD38 protein on cancer cell surface
CAR T-cell therapy with 19(T2)28z1XX targeting CD19 in clinical investigation
Ulocuplumab and other experimental monoclonal antibodies
BCL-2 inhibitors
Venetoclax being tested to trigger cancer cell death by blocking BCL-2 protein
Investigated in combination with other active agents
Plasmapheresis
Procedure to temporarily remove excess IgM protein from blood
Used to quickly relieve symptoms of hyperviscosity syndrome
Combined with other definitive treatments targeting the underlying disease
lightbulb Did you know?
01Remission periods after treatment can vary dramatically—some patients remain in remission for decades while others relapse within months, making each person's disease course highly unpredictable despite the cancer's generally slow-growing nature.
02The abnormal IgM protein produced by this cancer is so large that it can actually thicken the blood like syrup, causing a potentially dangerous condition called hyperviscosity syndrome that can affect vision, cause confusion, and impair circulation throughout the body.
03Approximately 90% of Waldenstrom's macroglobulinemia patients have a genetic mutation called MYD88, and about 40% have a mutation in CXCR4—these genetic profiles can actually predict how patients will respond to certain treatments and influence decisions about therapy selection.
Questions people often ask
info This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Belgium
